- Home
- REGN
as 09-11-2025 4:00pm EST
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
| Founded: | 1988 | Country: | United States |
| Employees: | N/A | City: | TARRYTOWN |
| Market Cap: | 59.5B | IPO Year: | 1991 |
| Target Price: | $794.83 | AVG Volume (30 days): | 991.3K |
| Analyst Decision: | Buy | Number of Analysts: | 23 |
| Dividend Yield: | Dividend Payout Frequency: | Quarterly | |
| EPS: | 39.67 | EPS Growth: | 5.03 |
| 52 Week Low/High: | $476.49 - $1170.58 | Next Earning Date: | 10-30-2025 |
| Revenue: | $14,214,200,000 | Revenue Growth: | 5.38% |
| Revenue Growth (this year): | -0.27% | Revenue Growth (next year): | 4.97% |
Latest Regeneron Pharmaceuticals Inc. News
REGN Breaking Stock News: Dive into REGN Ticker-Specific Updates for Smart Investing
Zacks
a day ago
Strength Seen in Travere (TVTX): Can Its 26.2% Jump Turn into More Strength?
BioPharma Dive
2 days ago
Kriya, Odyssey secure ‘megarounds’; Amgen boosts R&D leadership
Pharma Voice
2 days ago
Pharma’s new boomtown? Why drugmakers are setting up shop in a small Swiss city.
Benzinga
3 days ago
Regeneron's Libtayo Combo Achieves Nearly Double Survival Rate In Advanced Lung Cancer Compared To Chemotherapy
Clinical Trials Arena
3 days ago
Regeneron’s cat and birch allergy mAbs score in Phase III trials
MT Newswires
3 days ago
Regeneron Says 5-Year Data Show Libtayo Improved Survival Outcomes in Lung Cancer
GlobeNewswire
3 days ago
Libtayo® (cemiplimab) Plus Chemotherapy Results at Five Years Reinforce Significant and Durable Improvements in Survival Outcomes for Advanced Non-small Cell Lung Cancer
The Wall Street Journal
3 days ago
Health Care Roundup: Market Talk
Compare REGN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "REGN Regeneron Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.